Associated Papers
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
Clinicopathological and Gene Mutation Analysis of 27 Cases with Extranodal Rosai-Dorfman Disease.
Tang M et al.
Journal of Inflammation Research, 2022
UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma.
Bowman RL et al.
Life Science Alliance, 2021
34210801 (PubMed )
Supplement: LSA-2021-01135_TableS1.xlsx › Supp._Table_S1
Structural bioinformatics enhances mechanistic interpretation of genomic variation, demonstrated through the analyses of 935 distinct RAS family mutations.
Tripathi S et al.
Bioinformatics (oxford, England), 2021
33226070 (PubMed )
Supplement: btaa972_supplementary_data.zip › RAS_Manuscript_RMarkdown.tar.gz › RAS_Manuscript1.Revised › RAS_Variants_Scores.xlsx › Sheet1
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.
Etemadmoghadam D et al.
Cancer Research, 2017
28646021 (PubMed )
Supplement: 00085472can162224-sup-170263_3_unknown_upload_4011671_jp98gb.xlsx › Table_S11
Select a paper to view details